|
 |
|
| Hemophilia | |
| Hemophilia is a rare hereditary disorder in which the ability of patients' blood to clot is impaired. As a result, the patient suffers from excessive bleeding and uncontrolled internal bleeding, leading to pain and eventual permanent damage to joints and muscles. There are two different forms of hemophilia, both generated by mutations to distinct genes. Hemophilia A results from mutations that impair the production of active Factor VIII. Hemophilia B results from mutations that impair the production of active Factor IX. It has been reported that even with "proper treatment" the life expectancy of hemophilia patients is about 10 years less than for individuals without hemophilia. Increasingly, the normal mode of treatment for younger patients is a prophylaxis regimen where patients are infused, on average, two or three times per week to maintain a better circulating level of coagulation factor. Long term studies in Sweden and elsewhere demonstrate that such regimens greatly reduce if not eliminate progressive joint deterioration. Click here for information about Hemophilia A Click here for information about Hemophilia B |
|
 Home | About | Technology | Hemophilia | Clinical Programs | Community | Careers | Contact Us Terms & Conditions of Use | Note Regarding Forward-Looking Statements | Privacy Policy | Site Map © Biogen Idec - Biogen Idec is proud to be an Equal Opportunity Employer. |
